VC-backed Avrobio rolls out IPO
Cambridge, Massachusetts-based Avrobio, a developer of gene therapies for rare diseases, has raised $99.7 million for its IPO after pricing its over 5.2 million shares at $19 per share. The stock began trading June 21, 2018 on the NASDAQ under the ticker symbol "AVRO." Morgan Stanley, Cowen and Wells Fargo Securities are the lead underwriters. Avrobio's pre-IPO backers include Cormorant Asset Management, Surveyor Capital, Aisling, Brace Pharma Capital, Eventide Asset Management, Morningside, Atlas Venture, SV Health Investors and Clarus Ventures.
21 June 2018•2 mins read
